(Q33771811)

29 July 2017

title

Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond (English)

1 reference

29 July 2017

1 reference

Mousa SA

1

1 reference

29 July 2017

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

4

1 reference

29 July 2017

issue

12

1 reference

29 July 2017

page(s)

552-561

1 reference

Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Platelet activation in unstable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Biochemical evidence of platelet activation in patients with persistent unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Platelet activation in clinical coronary artery disease and spasm

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Calcium, calmodulin and protein kinase C dependence of platelet shape change

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

GPIIb-IIIa: the responsive integrin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

Long-term administration of glycoprotein IIb/IIIa antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901394-X

7 January 2021

10.1016/S1359-6446(99)01394-X

Identifiers

DOI

1 reference

29 July 2017

1 reference